Current Report Filing (8-k)
2022年4月20日 - 4:19AM
Edgar (US Regulatory)
0001662382
false
0001662382
2022-04-19
2022-04-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 19, 2022
BRAIN SCIENTIFIC INC.
(Exact name of registrant as specified in its
charter)
Nevada |
|
333-209325 |
|
81-0876714 |
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of Incorporation) |
|
File Number) |
|
Identification No.) |
6700 Professional Parkway
Lakewood Ranch, Florida 34240
(Address of Principal Executive Office) (Zip
Code)
(917) 388-1578
(Registrant’s telephone number, including
area code)
(Former Name or Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
None |
|
None |
|
None |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K includes information
that may constitute forward-looking statements. These forward-looking statements are based on the Company’s current beliefs, assumptions
and expectations regarding future events, which in turn are based on information currently available to the Company. By their nature,
forward-looking statements address matters that are subject to risks and uncertainties. Forward looking statements include, without limitation,
statements relating to projected industry growth rates, the Company’s current growth rates and the Company’s present and future
cash flow position. A variety of factors could cause actual events and results, as well as the Company’s expectations, to differ
materially from those expressed in or contemplated by the forward-looking statements. Risk factors affecting the Company are discussed
in detail in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent
required by applicable securities laws.
Item 7.01 Regulation FD Disclosure.
Pursuant to Regulation FD, Brain Scientific Inc.
(the “Company”) hereby furnishes investor presentation materials in the form of a power point presentation and description
of the Company’s potential technology and product offerings (the “Presentation Material”) written by the Company to
update current shareholders as well potential investors of the Company’s business strategy. The Company will present the Presentation
Material to investors, shareholders and/or customers on or after April 19, 2022.
The information
provided under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished” and shall not be
deemed “filed” with the Securities and Exchange Commission or incorporated by reference in any filing under the Securities
Exchange Act or 1934 or the Securities Act of 1933. The Presentation Material can also be found on our website at https://brainscientific.com.
Item 9.01. Financial Statements and Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Presentation Material |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
BRAIN SCIENTIFIC INC. |
|
|
|
Dated: April 19, 2022 |
By: |
/s/ Hassan Kotob |
|
|
Hassan Kotob
Chief Executive Officer |
|
|
Brain Scientific (CE) (USOTC:BRSF)
過去 株価チャート
から 5 2024 まで 6 2024
Brain Scientific (CE) (USOTC:BRSF)
過去 株価チャート
から 6 2023 まで 6 2024